Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference
Fate Therapeutics (NASDAQ: FATE) announced that its Chief Scientific Officer, Dan Shoemaker, Ph.D., will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 11:30 a.m. EST. A live webcast will be available on the company's investor relations website, with an archived replay to follow.
The company focuses on developing programmed cellular immunotherapies for cancer and immune disorders, utilizing its proprietary induced pluripotent stem cell (iPSC) platform.
- None.
- None.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Officer, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020, at 11:30 a.m. EST.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
FAQ
When will Fate Therapeutics present at the Wedbush PacGrow Healthcare Virtual Conference?
Who is presenting for Fate Therapeutics at the conference?
Where can I watch the Fate Therapeutics presentation?
What is the focus of Fate Therapeutics?
What platform does Fate Therapeutics use for its immunotherapies?
